Abstract
The authors present the results of domestic clinical trials on the efficacy and safety of mexidol in patients with cerebrovascular disorders including ischemic stroke (IS). The use of mexidol is associated with complete and rapid regression of the focal neurological deficit. Mexidol is well tolerated with no significant side-effects. The drug is recommended for enteral and parenteral administration in patients with IS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
